Bausch and Lomb's new owner posted a loss of more than $970 million last quarter.
Valeant Pharmaceuticals announced it lost $973 million in the third quarter.
The company said $305 million of the total loss was related to the acquisition of Bausch + Lomb. Of that $305 million, the report attributes $165 million of that total to employee severance costs.
Valent's acquisition of Bausch + Lomb was finalized in August. More than 400 people in Rochester lost their jobs.